Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/10587
EFFECTIVENESS OF MENINGOCOCCAL C CONJUGATE VACCINE IN SALVADOR, BRAZIL: A CASE-CONTROL STUDY
Vacinas meningococica
Epidemia
Vigilância
Masculino
Feminino
Controle
Brasil
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Municipal Secretary of Health of Salvador. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. Institute of Collective Health. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia.
Pan American Health Organization. Brasília, DF, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. School of Pharmacy. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. Institute of Collective Health. Salvador, BA, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia.
Pan American Health Organization. Brasília, DF, Brasil
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil / Federal University of Bahia. School of Pharmacy. Salvador, BA, Brasil
Resumo em Inglês
During a citywide epidemic of serogroup C meningococcal disease in Salvador in 2010,
Brazil, the state government initiated mass vaccination targeting two age groups with high
attack rates: individuals aged <5 years and 10–24 years. More than 600,000 doses of meningococcal
serogroup C conjugate vaccines were administered. We performed a casecontrol
study to evaluate vaccine uptake, document vaccine effectiveness and identify reasons
for non-vaccination.
Methods and Findings
Population-based surveillance identified patients with laboratory-confirmed invasive meningococcal
C (MenC) disease during 2010. Information on MenC vaccination was obtained from
case patients and age-matched individuals from the same neighborhoods. MenC vaccine effectiveness
was estimated based on the exact odds ratios obtained by conditional logistic regression
analysis. Of 51 laboratory-confirmed cases of serogroup C meningococcal disease
among patients <5 and 10–24 years of age 50 were included in the study and matched with
240 controls. Overall case-fatality was 25%.MenC vaccine coverage among controls increased
from 7.1%to 70.2% after initiation of the vaccination campaign. None of the 50 case
patients but 70 (29.2%) of the 240 control individuals, including 59 (70.2%) of 84 matched with
cases from the period afterMenC vaccination, had received at least one MenC vaccine dose.
Overall effectiveness of MenC was 98%with a lower 95%exact confidence limit of 89%.
Conclusions
MenC vaccines administered during the meningococcal epidemic were highly effective,
suggesting that rapid vaccine uptake through campaigns contributed to control of
meningococcal disease.
Palavras-chave
Doença meningococicaVacinas meningococica
Epidemia
Vigilância
Masculino
Feminino
Controle
Brasil
Compartilhar